

Global Presence, Deeply Engaged in Metabolic Diseases and Cancer Treatments

COMPANY PROFILE

Established in 2013 and located in the Chengdu High-Tech Industrial Development Zone, with a registered capital of USD 70 million, covering a site area of over 45,000m², and a completed construction area of approximately 30,000m². Relying on the Group's R&D strengths in biopharmaceuticals and international standard quality systems, DesigneRx Pharmaceuticals has built advanced peptide drug production lines, equipped with bio-fermentation and chemical synthesis production platforms, with end-to-end capabilities from lab-scale to large-scale production. We are committed to the development and manufacturing of premium quality peptide drugs for the global market.

Synthetic Peptides Solutions

DesigneRx Pharmaceuticals specializes in providing full-cycle peptide solutions from amino acid sequence design to Drug Substance (DS) or Active Pharmaceutical Ingredient (API), Finished Dosage Form(FDF).



Biopharmaceutical Solutions

DesigneRx Pharmaceuticals is committed to providing comprehensive biopharmaceutical solutions for clients worldwide, from early-stage R&D to commercial production.



Technical Advantages



APIs

GLP-1 Pipelines		
Name	Indication	DMF Filing
Semaglutide	Diabetes, Weight Management	2026.08
Tirzepatide	Diabetes, Weight Management	2027.12
Liraglutide	Diabetes, Weight Management	Under Development





Finished Products

Oncology Pipelines			
Name	Indication	Dosage form	IND Filing
Pegargiminase (ADI-PEG 20)	hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia	Inj	2026
Abemaciclib	early-stage breast cancer	Tab	Under Development
Olaparib	recurrent epithelial ovarian cancer, carcinoma of fallopian tube or primary peritoneal carcinoma	Tab	Under Development
Trilaciclib dihydrochloride	extensive-stage small cell lung cancer	Inj	Under Development

Non-oncology Pipelines			
Name	Indication	Dosage form	ANDA Filing
Semaglutide	Diabetes, Weight Management	Inj	2027
Liraglutide	Diabetes, Weight Management	Inj	Under Development
Tirzepatide	Diabetes, Weight Management	Inj	Under Development

· Synthetic Biology ·
 · Intelligent Pharma ·
 · Guarding Life ·
 · Serving the World ·
 · Creating the Future Together ·

CONTACT INFORMATION

 Tel 86-28-87927676 ext. 826
 E-mail business@polarispharma.com
 Website www.polarispharma.com
 Address Chengdu, China

Official Account



WeChat



WhatsApp

